and its effects on ambulatory and clinic BP and body fluid volumes. Results. Office BP similarly declined in the furosemide group (from 161 ± 14/80 ± 10 to 139 ± 14/74 ± 8 mmHg) and in controls (from 159 ± 16/81 ± 10 to 137 ± 16/75 ± 10 mmHg). We detected a greater reduction (P = 0.013) of LVMI in patients receiving furosemide (−7.9, IQR from −15.8 to −1.4 g/h 2.7 Introduction Non-dialysis chronic kidney disease (CKD) is a public health emergency because of the high and rapidly expanding prevalence in the general population [1, 2] . More importantly, CKD is characterized by remarkable cardiovascular (CV) risk [2] [3] [4] ; patients are in fact 8 to 35 times more likely to die from CV disease than to reach end-stage renal disease (ESRD) [4] . A powerful predictor of CV mortality in these patients is the representation of left ventricular hypertrophy (LVH) [5, 6] ; this complication, is common, and its prevalence increases with the reduction of glomerular filtration rate up to 75% in pre-ESRD [7] . In CKD, left ventricular growth is a remodelling process aimed at compensating the enhanced cardiac workload, secondary to blood pressure (BP) and volume overload. These alterations have been described since the early phases of CKD in association with hypertension; even moderate degrees of renal impairment are in fact associated with fluid and sodium retention and dependent hypertension [8] [9] [10] [11] .
Interestingly, removal of excess volume in haemodialysis patients by ultrafiltration and a reduction in salt intake leads to regression of left ventricular mass (LVM) [12, 13] . Conversely, whether the relationship between treatment of volume expansion and a reduction of LVM holds true also in non-dialysis CKD remains undefined. In this population, volume-dependent hypertension can be efficaciously corrected by loop diuretics [14] , but whether these drugs favourably affect LVM is still unknown.
We therefore designed a randomized controlled trial in hypertensive patients with CKD stage 3-4 (estimated creatinine clearance 60-15 mL/min/1.73 m²), treated with converting enzyme inhibitors (CEI) and/or angiotensin II receptor antagonist (ARA), which are drugs considered of first choice in CKD patients considered to be at risk of diabetes, CV disease or proteinuria [15] , to evaluate the effect of 12 months of add-on furosemide on LVM index (LVMI). Secondary aims were to verify safety related to furosemide treatment and its effects on ambulatory and clinic BP and body fluid volumes.
Materials and methods

Patient selection
Subjects considered eligible for the study were all consecutive incident CKD patients in the outpatient renal clinic of the Department of Nephrology at the Second University of Naples between 1 September 2005 and 30 September 2006 who were not on dialysis and without a kidney transplant.
Inclusion criteria were: age >18 years; creatinine clearance, estimated by Cockcroft and Gault formula corrected for body surface area (eCrCl-CG), ranging from 60 to 15 mL/min/1.73 m 2 ; treatment with either CEI or ARA; and systolic BP >140 mmHg. Exclusion criteria were: treatment with diuretics in the last month; acute kidney injury or change of eCrCl-CG >30% in the last 3 months; immunosuppressive therapy; oedematous states requiring diuretic therapy (heart failure NYHA class 3 and 4, advanced liver cirrhosis, and nephrotic syndrome); and active malignancy.
Informed consent was obtained from all subjects before randomization. The study was designed in accordance with the guidelines of the Declaration of Helsinki, approved by the local ethics committee and registered at ClinicalTrials.gov website (NCT00478543).
Study design
This was a randomized, open-label, active control, parallel-designed study. Patients satisfying selection criteria were considered for recruitment and underwent physical examination, BP and body weight measurement, blood sample collection, ambulatory BP (ABP) monitoring, bio-impedance analysis (BIA), and echocardiography.
After randomization, visits were scheduled at 6, 13, 26 and 52 weeks, when physical exam, office BP, body weight, and therapy were registered. At each visit, we also collected blood samples to measure creatinine, urea, sodium, potassium, uric acid, glucose, LDL cholesterol and haemoglobin, and 24-h urine samples to measure creatinine, sodium and protein.
Laboratory protocols were standardized with in-house analysis, including measurement of creatinine by modified kinetic Jaffé reaction, and proteinuria by pyrogallol red-molybdate method. Twenty-four-hour urine collection was considered inaccurate, and repeated within 1 week, if creatinine excretion was outside of the 60-140% range of the value calculated according to Dwyer and Kenler [16] .
Echocardiography, ABP monitoring and BIA were obtained at baseline and Week 52.
In order to minimize the effects of BP on primary outcome, in both groups, antihypertensive therapy was targeted at achieving clinic BP <130/ 80 mmHg. In the furosemide group, furosemide was administered orally with the initial dose being chosen on the basis of eCrCl-CG. Specifically, in patients with eCrCl-CG 59-45 mL/min/1.73 m 2 , starting dose was 25 mg/day, while those with eCrCl-CG 44-30 or 29-15 mL/min/1.73 m 2 received 50 or 75 mg/day, respectively. Furosemide was then up-titrated by 25 mg/day every 2 weeks in order to obtain either an optimal BP control (<130/80 mmHg) or a body weight loss of 5% with respect to baseline. In the latter case, if BP remained above the target, non-diuretic antihypertensive drugs were added. To allow adequate modulation of furosemide dose, patients were required to measure periodically body weight and BP at home. They were asked to call the nephrologists and eventually come to the office for extra visits in the following cases: body weight loss <0.5 or >1 kg/day during up-titration of furosemide, elevated BP values, systolic BP <100 mmHg, and symptoms of hypotension.
Similarly, in the control group, BP goal was pursued first by up-titrating dose of current antihypertensive drugs and, once maximal tolerated dose was reached, by adding further non-diuretic antihypertensive drugs. Antihypertensive drugs were chosen on the basis of compelling indications [17] . In this group, the use of furosemide was only permitted in the presence of marked peripheral oedema or dyspnoea secondary to volume expansion. These patients were also asked to monitor BP at home and call/see nephrologists in the case of poor BP control.
Patients were advised to follow a diet low in salt. Low protein diet (0.6 g/kg/day) was recommended only in CKD patients with eCrCl-CG ≤30 mL/min.
Outcomes
The primary aim was to evaluate the effect of a 1-year furosemide treatment on LVMI. Our hypothesis was that correction of volume overload by furosemide administration could be effective in reducing LVMI. Secondary aims were to verify (i) safety of furosemide-based regimen, (ii) the effects of treatment on ABP values and body fluid volumes, and (iii) the extra work of nephrologists related to diuretic therapy. Specifically, the primary outcome of this study was the difference in LVMI between the two study arms after 12 months of treatment, and secondary outcome measures were represented by (i) the incidence of hyperuricaemia (>7.5 mg/dL), hyperkalaemia (>5.5 mEq/L), hyponatraemia (<135 mEq/L), hypokalaemia (<3.5 mEq/ L), orthostatic hypotension (systolic BP <100 mmHg), peripheral pitting oedema (clinical assessment), and acute renal failure (eCrCl-CG decline >30% between two consecutive visits); (ii) differences in clinic and ABP and BIA-derived body fluid volume changes; and (iii) number of unscheduled visits.
Echocardiography
Echocardiographic evaluation was obtained using standard M-mode, twodimensional images, spectral and colour Doppler interrogation, using a commercially available echocardiograph (Vivid 7 Dimension-GE Healthcare Ultrasound). An average of three measurements were made for each variable, and images were digitally stored. Offline analysis was obtained using the workstation EchoPAC PC version 7.0.0 (GE Healthcare Ultrasound, Michigan, USA). Measurements were read blindly by two experienced cardiologists (S.T. and M.C.) and averaged. End-diastolic left ventricular internal diameters (LVIDd), end-diastolic posterior wall thickness (PWTd) and end-diastolic septal wall thickness (SWTd) were measured according to the recommendations of the American Society of Echocardiography [18] . LVM was calculated using the following formula:
LVM was corrected for height 2.7 in metres because this index correlates better with long-term outcomes independently from the extracellular volume expansion which is usually detected in CKD patients [19] ; correction for height 2.7 was also chosen a priori in order to avoid influence of different body surface area due to furosemide-induced changes of body weight. LVH was defined according to gender-specific criterion as LVMI >50 g/m 2.7 in men and >47 g/m 2.7 in women [20] . We also calculated the E/A ratio by standard Doppler echocardiography.
Blood pressure determinations
Office BP measurements were obtained by a nephrologist following the recommendations of the European Society of Hypertension [21] . In the morning (8-11 a.m.), patients were seated in a quiet environment for at least 15 min before BP measurement; then, using a mercury sphygmomanometer with a cuff size of appropriate dimension and with patients in the sitting and orthostatic posture, the first and fifth Korotkoff sound were used to define systolic and diastolic BP, respectively. The mean of three consecutive readings taken 2 min apart was considered for analysis of office BP measurements.
ABP measurements were always carried out on a working day by means of a Spacelabs 90207 monitor. The cuff size was chosen on the basis of the patient's arm circumference, and it was fixed to the nondominant arm. The monitor recorded BP every 15 min during the period from 7 a.m. to 11 p.m. and every 30 min during the period from 11 p.m. to 7 a.m. Daytime and night-time periods were derived from the diaries recorded by the patients during monitoring. Monitoring was considered adequate if ≥14 measurements were obtained during the day and ≥7 at night.
Bio-impedance analysis
Single-frequency BIA was determined on the non-dominant side of the body, injecting 800 μA and 50 kHz alternating sinusoidal current with a standard tetrapolar technique (BIA 101 Impedance Analyzer; Akern, Firenze, Italy) [10] . The BIA variables measured were resistance, reactance and phase angle. The BIA software used these parameters indexed to height and weight to determine the derived variables, such as total body water (TBW) and extracellular water (ECW).
Sample size and randomization
The report is in compliance with the recommended reporting guidelines for randomized controlled trials [22] . The primary end point was the change in LVMI with intervention. Sample size was so calculated to detect an effect size of 0.9 in the reduction of LVMI between the two groups with a power of 0.80 and a level of significance of 0.05. Based on this information, a sample size of 40 patients was required. We performed a pilot study to assess in a sample of our outpatient population the mean value and the standard deviation of LVMI; in the 25 patients studied, LVMI was 75 ± 11 g/h 2.7 . Under these conditions and assuming a correlation between two LVMI measures of 0.5, an effect size of 0.9 was consistent with a reduction of 10 g/h 2.7 that corresponded to a LVMI reduction of 13% with respect to baseline.
After suitable patients were selected, randomization was performed. The randomization process was centrally administrated by the participating statistician (P.C.) and stratified by eCrCl-CG value (59-45, 44-30 and 29-15 mL/min/1.73 m 2 ). Block randomization with a block size of four was performed using a SAS macro (SAS Institute, Cary, NC, USA). Implementation of the random allocation sequence was performed by central telephone. The statistician responsible for the randomization process masked the sequence until intervention was assigned. Then, an allocation number was communicated to the nephrologists who enrolled the patient and allocated the patient to the assigned group. Because of the nature of the study, neither the patients nor the nephrologists were blinded with respect to the specific intervention, whereas those assessing the outcomes (M.C. and S.T., cardiologists for assessment of LVMI and ABP and technician for BIA measures) were blinded to group assignment.
Statistical analysis
Continuous variables are reported as either mean ± SD (Gaussian distribution) or median and interquartile range (IQR) (non-Gaussian distribution). Comparison for primary outcome (difference of LVMI from baseline to Week 52 visit) was performed by Mann-Whitney test. Similarly, secondary outcomes were analysed by either Mann-Whitney test or Fisher exact test. Changes from baseline in the same study group were analysed with paired Student's t-test or Wilcoxon test on the basis of the variable's distribution. ANOVA for repeated measures, Kruskal-Wallis test and linear correlation analysis were also used where appropriate. A two-tailed P-value <0.05 was considered significant. Data were analysed using SPSS 12.0 (SPSS Inc, Chicago, IL, USA).
Results
We randomized 40 patients out of the screened population of 308 patients ( Figure 1) ; previous diuretic treatment was the most frequent reasons for exclusion (51%); these excluded patients were treated from a median of 5 months (IQR [4] [5] [6] [7] [8] . No dropout occurred during follow-up. The two study groups showed similar demographic, clinical and therapeutic features ( Table 1) . The cohort was characterized by a high CV risk profile, as evidenced by the high prevalence of diabetes and LVH.
According to the study design, office and ambulatory BP similarly decreased in the two arms ( Figure 2 and Table 2 ). At baseline, the prevalence of LVH was~70% in both groups; this corresponded to similar values of LVM indexed for height 2.7 (Table 3 ). The same held true when LVM was indexed for body surface area (124 ± 26 g/m 2 in the furosemide group and 120 ± 34 g/m 2 in control, P = 0.663). We observed a greater reduction of LVMI in the furosemide (−7.9 g/h 2.7 , IQR from −15.8 to −1.4) than in the control group (0.0 g/h 2.7 , IQR from −6.2 to +9.5, P = 0.013). In the furosemide group, reduction of LVMI was observed in all but four patients (80%), while in the control group, reduction of LVMI was detected in only nine patients (45%, P = 0.022) (Figure 3) . The subgroups of patients with regression of LVMI in the control and furosemide groups (n = 25) did not differ from those without regression of LVMI (n = 15) in terms of demographics (age, gender and BMI), clinical (diabetes, previous CV disease and basal BP) and laboratory parameters (eCrCl-CG, haemoglobin and proteinuria), and therapy (number of drugs and frequency of antihypertensive classes). The observed changes of LVMI at Week 52 in the furosemide group were due to a significant reduction of SWTd and PWTd (Table 3) . Conversely, these parameters remained unchanged in controls. At Week 52, the left atrial diameter (LAD) remained unchanged in the furosemide group, while it increased in controls. Furthermore, the ratio of peak early filling velocity to late filling velocity at atrial contraction (E/A ratio) did not change in the furosemide group, while it decreased in controls ( Table 3) .
The number of antihypertensive agents similarly increased from baseline to end of follow-up in the two groups (from 2.3 ± 1.0 to 3.5 ± 1.4 in control and from 2.4 ± 0.8 to 3.3 ± 1.0 in the furosemide group). Patients in the diuretic group received a mean first dose of furosemide of 59 ± 17 mg/day; this dose was maintained subsequently, being 61 ± 29 and 65 ± 34 mg/day at Week 26 and 52, respectively. In the control group, therapy intensification was mainly based on addition of calcium channel blockers (CCB) and beta-blockers; in particular, at the end of follow-up, the number of control patients receiving CEI, ARA, CCB, beta-blockers and other antihypertensive drugs was 14, 10, 19, 16 and 10, respectively. Furosemide was prescribed also in this group due to the development Fig. 1 . Enrolment, randomization and study completion. of oedema, but this occurred for a limited period of time (<2 weeks) and in only six patients. No patient developed dyspnoea during follow-up. The different antihypertensive approach was associated with different body weight changes in the presence of unvaried salt intake. In fact, as depicted in Table 4 , body weight significantly decreased in the furosemide group and remained unchanged in the controls, while 24-h urinary sodium excretion, which was analogous at baseline (154 ± 56 and 132 ± 78 mEq/day, in control and diuretic group, P = 0.326), did not change subsequently. Also, urinary urea levels were similar in the two groups of patients at baseline (18.5 ± 5.3 and 17.5 ± 3.8 g/day, in control and diuretic group, P = 0.406). BIA confirmed the different pattern of changes of volume status (Table 4 ). In the furosemide group, TBW declined by −1.6 L (IQR from −2.9 to −0.1), while it slightly increased in controls + 0.7 L (IQR from −0.7 to +2. A further difference was also observed in the antiproteinuric response; in the presence of similar basal levels of 24-h proteinuria (P = 0.841), the final value of proteinuria was significantly lower versus baseline only in the furosemide group (Table 4) . Reduction of proteinuria was in fact greater in the furosemide group (−57% IQR from −81 to −35) than 1.02 ± 0.13 1.06 ± 0.14 1.09 ± 0.14 0.96 ± 0. Furosemide and LVM index in CKDin controls (−1% IQR from −30 to +81) (P = 0.002). In both groups, renal function and haemoglobin levels remained stable throughout the observation period. Treatment with loop diuretics was well tolerated, and no patient required drug withdrawal. The most common side effects of furosemide treatment, such as hyponatraemia, hyperuricaemia and acute eCrCl-CG decline, did not occur more frequently than in controls (Table 5) ; conversely, the incidence of hyperkalaemia and peripheral oedema was lower in the furosemide group when compared with controls. Allopurinol was prescribed to at least one in nine patients in the control group and 11 patients in the furosemide group during follow-up (P = 0.752). Similarly, at each follow-up, the use of allopurinol did not differ between the two groups.
During the whole study period, however, unscheduled visits were more frequent in the furosemide group as compared with controls (8, IQR 6-10 versus 2, IQR 1-6, respectively, P < 0.0001). This difference was due to the higher number of patient contact required to titrate furosemide dose according to the changes of body weight and BP; conversely, the number of unscheduled laboratory exams did not change in the two groups (1, IQR 1-2 in the furosemide group and 1, IQR 0-3 in controls, P = 0.738).
Discussion
This is the first study providing evidence in the setting of non-dialysis CKD for regression of left ventricular mass 12.7 ± 1.6 12.2 ± 1.8 12.6 ± 1.8 12.5 ± 1.6 12.3 ± 1.4 12.5 ± 1.5 Serum uric acid (mg/dL) 6.5 ± 1.7 6.9 ± 1.5 7.3 ± 2.0 6.1 ± 1. by antihypertensive intervention. We found that in hypertensive CKD patients treated with RAS inhibitors, add-on furosemide therapy induced a significant decrease of LVMI. The beneficial effect is specifically related to the correction of excess volume, as testified by the reduction of both total and extracellular fluid compartments; on the contrary, in the control group, in the presence of comparable reduction in ambulatory and office BP, no change in LVMI was observed likely due to the unchanged volume overload. Our hypothesis is supported by the finding that, at variance with controls, in the furosemide group, correction of volume expansion significantly correlated with the decrease of LVMI. The beneficial effects of furosemide were obtained in the presence of comparable office and ambulatory BP levels in the two study arms. In particular, we found a marked difference between office and ABP monitoring systolic BP values; a similar discrepancy has been previously reported in two papers by our group [23, 24] . Furthermore, a recent meta-analysis showed that a consistent percentage (~30%) of CKD patients have white coat hypertension [25] .
The above-mentioned beneficial effect of furosemide is of interest because previous studies in patients with essential hypertension and in spontaneously hypertensive rats have shown that addition of diuretics to RAS inhibitors is associated with larger reduction in the cardiac mass and concurrent significantly greater decrease of BP as compared with monotherapy with RAS inhibitors [26, 27] . Similarly, intensive ultrafiltration in dialysis patients induced regression of LVMI, but this effect was still associated with significantly lower BP values [12, 13] . Indeed, at variance with all the previous studies, the current trial was specifically designed to evaluate the effect of furosemide on LVMI independently from BP changes.
Theoretically, the modifications of cardiac mass can be secondary to the reduction of two distinct histopathological components, that is cellular hypertrophy and/or interstitial fibrosis. This study cannot discern between the two mechanisms; however, it is possible to hypothesize that the regression of LVMI induced by furosemide was secondary to a decrease of cellular hypertrophy. Indeed, furosemide does not decrease myocardial collagen accumulation in patients or rats with heart failure [28, 29] . Our alternative hypothesis, since RAS inhibitors reduce the degree of myocardial fibrosis in hypertensive patients [30] , RAS activation secondary to sodium and fluid losses by diuretic treatment may have resulted in the enhancement of the antifibrotic efficacy of RAS inhibitors. A similar synergic action has been suggested to explain the improvement of the antiproteinuric efficacy of RAS inhibitors after add-on diuretic therapy [31, 32] . In this regard, it is interesting that we observed a significant decrement of proteinuria only in the furosemide group.
More importantly, in a previous study on dialysis [33] , an increase of 12 g/m 2.7 of LVMI in 1-year interval was associated with a 62% increase in the incident risk of fatal and non-fatal CV events in the subsequent follow-up. In the present trial, add-on furosemide for 1 year induced a regression of 7.9 g/m 2.7 of LVMI on average (Figure 3 ). The present date therefore, suggests there are also beneficial effects of furosemide on CV prognosis in the non-dialytic stage of CKD; however, long-term studies are required to confirm wether partial regression of LVMI positively impacts on outcomes.
A further important echocardiographic finding is demonstrated by the prevention in the furosemide group of the increment of LAD observed in control patients. Again, this effect was likely secondary to the better control of body fluid volumes. International guidelines recommend monitoring of LAD or atrial volume in the general hypertensive population because enlargement of left atrium heralds adverse CV outcomes [18] . This association has been recently confirmed in dialysis patients; the increment of left atrial volume in these patients, in fact, predicts CV events independently of the basal value and of the LVM as well [34] . Finally, we detected a reduction of E/A ratio in the control group but not in the furosemide group; this difference may extend the negative effects of volume excess to LV relaxation.
The gradual and careful up-titration of furosemide dose likely accounts, at least in part, for the remarkable tolerability of this drug. We did not in fact detect in this group any withdrawal or significant metabolic complication that, on the contrary, have been often reported in other studies [35, 36] . We cannot exclude, however, that the selection criteria may have played a role. Indeed, enrolled patients had on average moderate degrees of renal disease and were not frankly oedematous. Similar patient characteristics have, in fact, allowed in previous studies the use of moderate doses of furosemide without any diuretic withdrawal or relevant reduction in eCrCl-CG [37, 38] ; on the contrary, the rate of adverse effects may rise in the presence of high furosemide doses typically required in the more advanced stages of CKD, which are not rarely coupled with remarkable oedema or oligoanuria. An additional factor underlying the tolerability of furosemide was represented by the frequent contacts with nephrologists in this group. The greater number of unscheduled visits in the furosemide group was generally required to readjust diuretic dose likely because of the substantial inter-patient and intra-patient variability of bioavailability of oral furosemide [39] .
On the other hand, control patients showed, in spite of the occasional use of furosemide, a greater incidence of peripheral pitting oedema. This finding is expected because lack of systematic diuretic treatment combined with larger prescription of vasodilating drugs markedly favours sodium retention in CKD [11] . Similarly, control patients also showed higher values of serum potassium and more frequent episodes of hyperkalaemia. This result is clinically important since CKD patients are particularly exposed to hyperkalaemia. Most CKD patients at stage 3 and 4, have potassium homeostasis in the high-normal range and often use several drugs that further rise serum potassium (RAS inhibitors, antagonist of ß-adrenergic system) with higher risk of life-threatening hyperkalaemia [40] [41] [42] . These specific conditions, together with moderate doses of furosemide, may account for the absence of hypokalaemia during diuretic treatment. Overall, the safety data of this study suggest that adequate doses of loop diuretic appear to be 'the good companion' of cardio-nephroprotective drugs not only in terms of efficacy but also for the prevention of iatrogenic complications [42] . Some important limitations of the current study must be highlighted. The study was performed in a single centre, and the number of selected patients was limited; in particular, 49 patients refused consent to participate because they considered the protocol too time cosuming. The strict monitoring required, therefore, limits the applicability of careful up-titration of furosemide only to extremely dedicated patients. In addition, nephrologists were not blinded with respect to the specific intervention because furosemide was up-titrated in relation to BP response and body weight change; however, the investigators assessing primary and secondary laboratory and instrumental outcomes were blinded to group assignment.
Despite such limitations, to our knowledge, this is the first study that evaluates long-term treatment by loop diuretics in hypertensive patients with CKD; in this population the effects of loop diuretics have only been evaluated in studies with a short follow-up period [8, 37] .
In conclusion, this trial demonstrates that in hypertensive CKD patients treated with RAS inhibitors, add-on furosemide therapy sustained for 1 year reduces LVMI and prevents enlargement of the left atrium. These effects are secondary to correction of volume overload and independent from BP. The beneficial effects of furosemide are not encumbered by significant adverse events while being associated with minor incidence of hyperkalaemia and peripheral oedema. Extra work however, is required to assist physicians in order to ensure adequate modulation of drug doses and, consequently, to optimize the effectiveness of this therapy. Further studies are required to verify the effect of furosemide-induced LVMI reduction on CV risk in CKD population.
